Prescient Therapeutics Limited (ASX:PTX)

Market Cap	40.19M
Revenue (ttm)	3.02M
Net Income (ttm)	-7.07M
Shares Out	980.32M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,115,584
Average Volume	1,089,963
Open	0.0430
Previous Close	0.0410
Day's Range	0.0410 - 0.0430
52-Week Range	0.0370 - 0.0630
Beta	0.51
RSI	39.02
Earnings Date	Aug 22, 2025

About Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PTX

Financial Performance

In 2024, Prescient Therapeutics's revenue was 3.71 million, an increase of 52.89% compared to the previous year's 2.43 million. Losses were -8.24 million, 17.6% more than in 2023.